Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX20 (abbreviation DDX20), also known as DP103 and Gemin3, is a member of the DEAD-box protein family defined by the highly conserved Asp–Glu–Ala–Asp (DEAD) motif. It functions as an RNA helicase with ATPase activity, modulating RNA structure in key cellular processes such as translation initiation, pre-mRNA splicing, miRNA maturation, and ribonucleoprotein assembly. DDX20 is essential for the assembly of small nuclear ribonucleoproteins (snRNPs) through its key role in the survival motor neuron (SMN) complex. It regulates gene expression through interactions with multiple transcription factors (e.g., SF-1) and coregulatory proteins, thereby affecting processes such as cell growth, apoptosis, and innate immunity signaling. DDX20 also influences disease states, with roles in cancer, spinal muscular atrophy, and viral infections, demonstrating tissue-dependent oncogenic or tumor suppressive functions, and participates in the regulation of pathways like NF-κB and p53 signaling. No direct clinical drugs are currently established for this target, but it is relevant in ongoing research on transcriptional and post-transcriptional regulation, neurodegeneration, and cancer biology.
DDX20 functions through modulation of RNA secondary structure via its ATP-dependent helicase activity. It regulates snRNP and snoRNP biogenesis and interacts with and suppresses key transcription factors via direct protein-protein interaction. Additionally, it facilitates miRNA gene silencing and post-transcriptional regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX20 (DDX20).